MODULATION OF SYNOVIAL FIBROBLAST PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR PRODUCTION BY PROTEIN-KINASE-C

被引:6
|
作者
UHL, J
NEWTON, RC
GROSS, JL
ROMMI, W
MOCHAN, E
机构
[1] DUPONT CO,DEPT MED PROD,GLENOLDEN,PA 19036
[2] UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT BIOCHEM,CAMDEN,NJ
[3] UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT FAMILY MED,CAMDEN,NJ
关键词
SYNOVIAL FIBROBLAST; PROTEIN KINASE-C; PLASMINOGEN ACTIVATOR INHIBITOR;
D O I
10.1016/0925-4439(91)90082-K
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phorbol myristate acetate (PMA) added to human synovial fibroblast cultures caused a dose-dependent increase in the production of plasminogen activator inhibitor-type 1 (PAI-1). In addition, PMA inhibited endogeneous and interleukin-1 (IL-1) induced plasminogen activator (PA) activity, while increasing mRNA PAI-1 levels. Other protein kinase C (PKC) activators, mezerein and teleocidin B4, caused similar effects. The simultaneous addition of the PKC antagonists, H-7 or staurosporine, prevented the inhibition of PA activity by PMA. This study shows that activation of PKC inhibits PA and stimulates PAI production in human synovial fibroblasts. These results suggest that activation of PKC may play an important role in regulating increased PA production associated with joint destruction in rheumatoid arthrits (RA).
引用
收藏
页码:283 / 288
页数:6
相关论文
共 50 条
  • [11] NEUTRALIZATION BY PLASMINOGEN-ACTIVATOR INHIBITOR-1 OF MUTANTS OF TISSUE PLASMINOGEN-ACTIVATOR
    BERGUM, PW
    ERICKSON, LA
    ENZYME, 1988, 40 (2-3) : 122 - 129
  • [12] TISSUE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR IN PATIENTS WITH LIVER-CIRRHOSIS
    LASIERRA, J
    AZA, MJ
    VILADES, E
    POBLET, S
    BARRAO, F
    BAYON, E
    GONZALEZ, J
    FIBRINOLYSIS, 1991, 5 (02) : 117 - 120
  • [13] EXPRESSION OF PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR BY RAT MESOTHELIOMA INDUCED BY ASBESTOS
    LENZ, SP
    GREEN, FHY
    MURPHY, PG
    LEE, M
    HART, DA
    CANCER LETTERS, 1993, 68 (2-3) : 119 - 127
  • [14] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR IN RAYNAUD PHENOMENON
    SILVERI, F
    SERRETTI, R
    CORE, P
    BRECCIAROLI, D
    THROMBOSIS RESEARCH, 1993, 70 : S93 - S93
  • [15] PRODUCTION OF VARIOUS FORMS OF PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR BY CULTURED MAMMARY EPITHELIAL-CELLS
    HEEGARD, CE
    WHITE, JH
    ZAVIZION, B
    TURNER, JD
    POLITIS, I
    JOURNAL OF DAIRY SCIENCE, 1994, 77 (10) : 2949 - 2958
  • [16] ON THE REVERSIBLE INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND WITH UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    LIJNEN, HR
    VANHOEF, B
    COLLEN, D
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (07) : 4041 - 4044
  • [17] CALCITRIOL-MEDIATED MODULATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-2
    KOLE, KL
    GYETKO, MR
    SIMPSON, RU
    SITRIN, RG
    BIOCHEMICAL PHARMACOLOGY, 1991, 41 (04) : 585 - 591
  • [18] PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR ACTIVITIES IN MEN WITH CORONARY-ARTERY DISEASE
    OSEROFF, A
    KRISHNAMURTI, C
    HASSETT, A
    TANG, D
    ALVING, B
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1989, 113 (01): : 88 - 93
  • [19] MODULATION OF THE MALIGNANT PHENOTYPE WITH THE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND THE TYPE-I PLASMINOGEN-ACTIVATOR INHIBITOR
    SORDAT, B
    REITER, L
    CAJOT, JF
    CELL DIFFERENTIATION AND DEVELOPMENT, 1990, 32 (03): : 277 - 286
  • [20] ALTERATIONS IN PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR LEVELS DURING LIVER-TRANSPLANTATION
    VIRJI, MA
    AGGARWAL, S
    KANG, Y
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (03) : 3540 - 3541